glp-1 news november 6 2025 Weight-loss drug makers announce pricing agreement with Trump GLP-1 Shortage = Over -

Additionally, some participants experienced diarrhoea severe enough to discontinue treatment, highlighting the clinical relevance of these side effects on electrolyte balance

Knowledge Center The Cerabeta blog is filled with the facts Check out the Cerabeta blog to learn important information about barley beta-glucan, cholesterol, weight loss, prebiotics and more

Key Takeaways GLP-1 medications are associated with a higher risk of gallstones and gallbladder disease, and FDA labeling for Zepbound and Wegovy lists gallstones and acute cholecystitis as possible risks

Faster visible results due to the immediate fat reduction in targeted areas

[DOI] [PubMed] [Google Scholar] 287.Alberici A, Bocchio L, Geroldi C, Zanardini R, Bonomini C, Bugari G, et al